Skip to main content
. 2023 May 26;11(6):1546. doi: 10.3390/biomedicines11061546

Figure 5.

Figure 5

Attenuation of neuroinflammation by COR167 in LPS-stimulated BV2 cells. (A) COR167 dose-response curve (0.1–100 µM) for cell viability in BV2 cells. CT: control untreated cells. ** p < 0.01. (B) Ameboid-like morphology of LPS-stimulated BV2 cells that was prevented by COR167 10 µM pretreatment. AM630 (1 µM) prevented the COR167 effect. (C) COR167 attenuated the reduction of cell viability induced by LPS exposure. This effect was antagonized by AM630 co-treatment. * p < 0.05, ** p < 0.01, *** p < 0.001. (D) COR167 abolished the LPS-induced HDAC1 overexpression in BV2 cells with an intensity comparable to SAHA 5µM. AM630 co-treatment completely antagonized this effect. ** p < 0.01, **** p < 0.0001.